LIMN
Liminatus Pharma, Inc. Class A Common Stock
NASDAQ: LIMN · HEALTHCARE · BIOTECHNOLOGY
$0.20
-0.15% today
Updated 2026-04-30
Market cap
$9.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.43
Dividend yield
—
52W range
$0 – $34
Volume
5.0M
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | $276.44M | $15.49M | $4.50M | $2.83M |
| Cash & equivalents | $336228.00 | $5.05M | $434000.00 | $804538.00 |
| Current assets | $421922.00 | $360649.00 | $210881.00 | $812658.00 |
| Total liabilities | $21.57M | $14.19M | $15.19M | $18.70M |
| Current liabilities | $1.38M | $3.59M | $5.16M | $8.68M |
| Long-term debt | — | — | — | — |
| Shareholder equity | $254.87M | $1.29M | $-10.69M | $-15.87M |
| Retained earnings | $-21.13M | $-13.97M | $-14.88M | $-17.52M |
| Accounts receivable | $1256.00 | $100000.00 | $945000.00 | $6456.00 |
| Inventory | — | — | — | — |
| Goodwill | — | — | — | — |